Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
T Cell Activation and Clonal Selection01:22

T Cell Activation and Clonal Selection

T cells are integral to our adaptive immune system, recognizing and effectively responding to foreign antigens. T cell activation and clonal selection are pivotal in orchestrating this immune response. This article elucidates these mechanisms, detailing the roles of cluster of differentiation (CD) markers, major histocompatibility complex (MHC) molecules, costimulatory signals, and the process of clonal selection.
Naive T cells that have not yet encountered an antigen express two primary CD...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same authorSame journal

Next-generation LMP2A-targeting TCR-recombinant T cells with inducible IL-18 expression to treat EBV-associated malignancies.

Molecular therapy. Oncology·2026
Same author

Factors influencing proprioceptive accuracy: An analysis of the joint position reproduction test.

Biological psychology·2026
Same author

In Remembrance of Professor Zelig Eshhar: <i>A Life Committed to CAR-T</i>.

Human gene therapy·2026
Same author

Ten years of translational innovation in HER2-targeted immune cell therapy - A comprehensive review of the work of the University of Debrecen Cell and Molecular Therapy Research Group.

Magyar onkologia·2026
Same author

Boosting the Activity of Melanoma-Targeting CAR-T Cells in the Presence of Citrate by the Application of Gluconate.

Pharmaceutics·2026
Same author

Blocking CD30 on CD19 CAR T cells augments their functional capacities against B-cell leukemia/lymphoma.

Frontiers in immunology·2026

Related Experiment Video

Updated: Jul 15, 2026

High-Efficiency Generation of Antigen-Specific Primary Mouse Cytotoxic T Cells for Functional Testing in an Autoimmune Diabetes Model
11:31

High-Efficiency Generation of Antigen-Specific Primary Mouse Cytotoxic T Cells for Functional Testing in an Autoimmune Diabetes Model

Published on: August 16, 2019

Augmenting CAR T cell functionality and metabolism through CD39 downtuning.

Dennis Christoph Harrer1,2, Jeremy Baldwin3,4, Markus Barden2

  • 1Department of Hematology and Internal Oncology, University Hospital Regensburg, 93053 Regensburg, Germany.

Molecular Therapy. Oncology
|July 13, 2026
PubMed
Summary

Downregulating CD39 in CAR T cells enhances their anti-tumor activity by improving function and controlling gastric cancer. This strategy boosts T cell capabilities, offering a promising approach for cancer immunotherapy.

Keywords:
CAR T cellCD39adenosineadoptive T cell therapyexhaustionmetabolism

More Related Videos

Efficient Generation of Murine Chimeric Antigen Receptor (CAR)-T Cells
06:22

Efficient Generation of Murine Chimeric Antigen Receptor (CAR)-T Cells

Published on: February 2, 2024

Manufacturing Chimeric Antigen Receptor (CAR) T Cells for Adoptive Immunotherapy
06:51

Manufacturing Chimeric Antigen Receptor (CAR) T Cells for Adoptive Immunotherapy

Published on: December 17, 2019

Related Experiment Videos

Last Updated: Jul 15, 2026

High-Efficiency Generation of Antigen-Specific Primary Mouse Cytotoxic T Cells for Functional Testing in an Autoimmune Diabetes Model
11:31

High-Efficiency Generation of Antigen-Specific Primary Mouse Cytotoxic T Cells for Functional Testing in an Autoimmune Diabetes Model

Published on: August 16, 2019

Efficient Generation of Murine Chimeric Antigen Receptor (CAR)-T Cells
06:22

Efficient Generation of Murine Chimeric Antigen Receptor (CAR)-T Cells

Published on: February 2, 2024

Manufacturing Chimeric Antigen Receptor (CAR) T Cells for Adoptive Immunotherapy
06:51

Manufacturing Chimeric Antigen Receptor (CAR) T Cells for Adoptive Immunotherapy

Published on: December 17, 2019

Area of Science:

  • Immunology
  • Cancer Biology
  • Metabolic Pathways

Background:

  • The CD39/CD73 axis suppresses T cell function.
  • CAR T cell activation increases CD39 expression, creating a negative feedback loop.
  • Targeting CD39 may enhance CAR T cell efficacy.

Purpose of the Study:

  • To investigate the impact of CD39 downregulation on CAR T cell functionality and anti-tumor activity.
  • To compare the performance of CD39-low CAR T cells with conventional CAR T cells.
  • To explore the potential of CD39 downregulation as a therapeutic strategy in cancer immunotherapy.

Main Methods:

  • Generated CD39-low CAR T cells.
  • Assessed T cell function, mitochondrial activity, and glycolytic pathways.
  • Evaluated anti-tumor efficacy in a CEA+ gastric carcinoma xenograft mouse model.
  • Compared CD39-low CAR T cells with conventional CAR T cells and CD38-downregulated CAR T cells.

Main Results:

  • CD39 downregulation enhanced CAR T cell functional capacities, including granzyme/perforin production and degranulation.
  • CD39-low CAR T cells exhibited superior mitochondrial function and glycolytic activity.
  • CD39-low CAR T cells demonstrated improved control of gastric carcinoma in vivo.
  • Downregulating CD38 did not yield similar benefits under stimulatory stress conditions.

Conclusions:

  • CD39 downregulation augments T cell anti-tumor activities by reducing AMP and adenosine-mediated repression.
  • CD39-low CAR T cells represent a promising strategy for enhancing cancer immunotherapy.
  • CD39 downregulation may be most effective as part of combination therapies targeting metabolic or immune checkpoint pathways.